Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | TKT | P29401 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | MPI | P34949 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | ERN1 | O75460 | 2/20 | 0.32 |
| ▸ | CRHBP | P24387 | 1/20 | 0.32 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7261717 | 0.82 | PLAU (0.40) | TDP1ALDH1A1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL19499817 | 0.78 | IDO1 (0.37) | IDO1ALDH1A1KDM4EMAPTCRHBP | |
| SCHEMBL844587 | 0.77 | ALDH1A1 (0.47) | TDP1ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL30492852 | 0.77 | ALDH1A1 (0.47) | TDP1ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL29955480 | 0.76 | ALDH1A1 (0.46) | TDP1ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1602516 | 0.76 | ALDH1A1 (0.46) | TDP1ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL14011344 | 0.74 | TDP1 (0.39) | TDP1ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL3509732 | 0.74 | TDP1 (0.39) | TDP1ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL29950698 | 0.74 | TDP1 (0.39) | TDP1ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL15228299 | 0.74 | ERN1 (0.41) | TDP1IDO1ALDH1A1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346574-A1 | PYRIDINYL SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-11-13 | — | — | US | disclosed |
| EP-4320125-A1 | PYRIDINYL SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | Bristol-Myers Squibb Company (US) | 2024-02-14 | — | — | EP | disclosed |
| CN-117396477-A | Pyridyl-substituted oxoisoindoline compounds for the treatment of cancer | 百时美施贵宝公司 | 2024-01-12 | — | — | CN | disclosed |
| CN-117321051-A | Compounds as PARP inhibitors | 重庆复尚源创医药技术有限公司 | 2023-12-29 | — | — | CN | disclosed |
| WO-2022228387-A1 | COMPOUNDS AS PARP INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2022-11-03 | — | — | WO | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| WO-2022216573-A1 | PYRIDINYL SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-10-13 | — | — | WO | disclosed |
| US-20220251081-A1 | HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER | LES LABORATOIRES SERVIER (FR) | 2022-08-11 | — | — | US | disclosed |
| US-20220220111-A1 | 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF | NUVATION BIO OPERATING COMPANY INC (US) | 2022-07-14 | — | — | US | disclosed |
| US-20220220111-A1 | 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF | NUVATION BIO OPERATING COMPANY INC (US) | 2022-07-14 | — | — | US | disclosed |
| CN-107873031-A | Benzoxazinone derivatives and analogs thereof as modulators of TNF activity | UCB生物制药私人有限公司 | 2018-04-03 | — | — | CN | disclosed |
| WO-2016198400-A1 | BENZOXAZINONE DERIVATIVES AND ANALOGUES THEREOF AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2016-12-15 | — | — | WO | disclosed |
| EP-1858888-B1 | HETEROARYL SUBSTITUTED PYRAZINYL-PIPERAZINE-PIPERIDINES WITH CXCR3 ANTAGONIST ACTIVITY | MERCK SHARP & DOHME (US) | 2013-04-17 | — | — | EP | disclosed |
| WO-2012098066-A1 | 1,6- AND 1,8-NAPHTHYRIDINES USEFUL AS DYRK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | WO | disclosed |
| WO-2012098066-A1 | 1,6- AND 1,8-NAPHTHYRIDINES USEFUL AS DYRK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | WO | disclosed |
| US-20120184562-A1 | 1,6- AND 1,8-NAPHTHYRIDINES | LUK KIN-CHUN (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184562-A1 | 1,6- AND 1,8-NAPHTHYRIDINES | LUK KIN-CHUN (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184562-A1 | 1,6- AND 1,8-NAPHTHYRIDINES | LUK KIN-CHUN (US) | 2012-07-19 | — | — | US | disclosed |
| US-8207170-B2 | Heterocyclic substituted piperazines with CXCR3 antagonist activity | SCHERING CORPORATION (US) | 2012-06-26 | — | — | US | disclosed |
| US-20110065651-A1 | HETEROCYCLIC SUBSTITUTED PIPERAZINES WITH CXCR3 ANTAGONIST ACTIVITY | SCHERING CORPORATION (US) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220220111-A1 | 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF | NME1, ADORA2A, GPR68 | TDP1 1401/4885IDO1 1320/4885ALDH1A1 1543/4885 |
| US-20110065651-A1 | HETEROCYCLIC SUBSTITUTED PIPERAZINES WITH CXCR3 ANTAGONIST ACTIVITY | CXCR3, CXCR1, CCR5 | TDP1 2790/4885IDO1 257/4885ALDH1A1 898/4885 |
| US-20250346574-A1 | PYRIDINYL SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | RECQL, H1-5, H1-3 | TDP1 1346/4885IDO1 1381/4885ALDH1A1 3170/4885 |
| US-20120184562-A1 | 1,6- AND 1,8-NAPHTHYRIDINES | PSEN1, BRCA1, PSEN2 | TDP1 69/4885IDO1 1320/4885ALDH1A1 738/4885 |
| US-20220251081-A1 | HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER | MAT2A, MAT2B, MAT1A | TDP1 160/4885IDO1 1961/4885ALDH1A1 1027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.